ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1076

Phospholipase C-eta2, As a C2 Domain-Containing Protein, Regulate Aggressiveness of Fibroblast‐like Synoviocytes and Ameliorate Arthritis in Experimental Animal Models of Rheumatoid Arthritis

Mingyo Kim, Hyun Min Jeon, Hae Sook Noh, Sang Mi Yi and Sang-Il Lee, Department of Internal Medicine and Institute of Health Science, Gyeongsang National University School of Medicine, Jinju, Korea, Republic of (South)

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Animal models, phospholipase, rheumatoid arthritis, synovial fluid, synovium and synovial cells

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, October 22, 2018

Title: Rheumatoid Arthritis – Etiology and Pathogenesis Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: The C2 domain is a Ca2+-dependent membrane-targeting motif found in many cellular proteins involved in signal transduction or inflammatory pathway. However, the effects of C2 domain-containing proteins in the pathogenesis of rheumatoid arthritis (RA) have not yet been elucidated. This study aims at screening the novel C2 domain-containing proteins related to the aggressiveness of RA fibroblast-like synoviocyte (RA-FLS) and confirm its precise roles in RA.

Methods: A recombinant adenovirus library expressing 145 kinds of C2 domains was transduced into RA-FLS to check the effects on the proliferation and NF-kB activation. Phospholipase C-eta2 (PLCH2) was selected as a target for C2 domain-containing protein. Recombinant adenovirus expressing PLCH2 (Adv-PLCH2) or C2 domain of PLCH2 (Adv-PLCH2_C2) were used for in vitro experiments using RA-FLS and MH7A cell line. The effect on the cell death of PLCH2 was assessed in vivo using a mouse Matrigel-plug model. Collagen-induced arthritis (CIA) model is also used to investigate the anti-arthritic effects of Adv-PLCH2, Adv-PLCH2_C2, and m-3M3FBS (PLC activator).

Results: PLCH2 levels were decreased in the RA-synovium and RA-FLS compared to osteoarthritis (OA), and further reduced after stimulation of LPS. Adv-PLCH2 and Adv-PLCH2_C2 suppressed proliferation, migration, invasion, NF-κB activation, cytokines/proteases production of RA-FLS and MH7A cell line. Adv-PLCH2 and Adv-PLCH2_C2 sensitized RA-FLS to apoptosis in vitro and in vivo model. Adv-PLCH2 or Adv-PLCH2_C2, as an intra-articular delivery, and m-3M3FBS, as systemic delivery of PLC activator, ameliorated inflammation and bone destruction in CIA mice.

Conclusion: Our data identify that PLCH2 and its activation efficiently suppress the aggressiveness of RA-FLS and inflammatory arthritis of CIA and suggest that PLCH2 may be an intriguing therapeutic target in RA.


Disclosure: M. Kim, None; H. M. Jeon, None; H. S. Noh, None; S. M. Yi, None; S. I. Lee, None.

To cite this abstract in AMA style:

Kim M, Jeon HM, Noh HS, Yi SM, Lee SI. Phospholipase C-eta2, As a C2 Domain-Containing Protein, Regulate Aggressiveness of Fibroblast‐like Synoviocytes and Ameliorate Arthritis in Experimental Animal Models of Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/phospholipase-c-eta2-as-a-c2-domain-containing-protein-regulate-aggressiveness-of-fibroblast%e2%80%90like-synoviocytes-and-ameliorate-arthritis-in-experimental-animal-models-of-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/phospholipase-c-eta2-as-a-c2-domain-containing-protein-regulate-aggressiveness-of-fibroblast%e2%80%90like-synoviocytes-and-ameliorate-arthritis-in-experimental-animal-models-of-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology